A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia

Kenneth S. Bauer, Judith E. Karp, Tushar S. Garimella, Suhlan Wu, Ming Tan, Douglas D. Ross

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences